Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

70.90USD
12 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$70.90
Open
$70.79
Day's High
$72.10
Day's Low
$69.82
Volume
2,023,066
Avg. Vol
1,887,310
52-wk High
$110.20
52-wk Low
$66.62

Latest Key Developments (Source: Significant Developments)

Celgene Corp, Acceleron Pharma Announce Results Of Phase 3 Medalist Trial Evaluating Luspatercept In Patients With Myelodysplastic Syndromes
Sunday, 2 Dec 2018 

Dec 2 (Reuters) - Celgene Corp ::ORATION AND ACCELERON PHARMA ANNOUNCE RESULTS OF THE PHASE 3 MEDALIST TRIAL EVALUATING LUSPATERCEPT IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AT THE ASH 2018 PLENARY SESSION.REGULATORY SUBMISSIONS PLANNED IN UNITED STATES AND EUROPE IN FIRST HALF OF 2019.MEDALIST MET PRIMARY ENDPOINT OF RED BLOOD CELL TRANSFUSION INDEPENDENCE (RBC-TI) FOR 8 OR MORE WEEKS DURING FIRST 24 WEEKS OF STUDY.  Full Article

FDA Says Symptoms Of Differentiation Syndrome Are Not Being Recognized With Idhifa
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - U.S. Food and Drug Administration::FDA WARNS THAT SYMPTOMS OF A SERIOUS CONDITION AFFECTING THE BLOOD CELLS ARE NOT BEING RECOGNIZED WITH THE LEUKEMIA MEDICINE IDHIFA (ENASIDENIB).FDA - IDHIFA PRESCRIBING INFORMATION AND PATIENT MEDICATION GUIDE ALREADY CONTAIN A WARNING ABOUT DIFFERENTIATION SYNDROME..FDA - BECOME AWARE OF CASES OF DIFFERENTIATION SYNDROME IN PATIENTS RECEIVING IDHIFA NOT BEING RECOGNIZED, PATIENTS NOT RECEIVING NECESSARY TREATMENT.FDA - IDHIFA IS MANUFACTURED FOR AND MARKETED BY CELGENE, LICENSED FROM AGIOS PHARMACEUTICALS.FDA - HEALTH CARE PROFESSIONALS SHOULD ALSO BE VIGILANT IN MONITORING FOR DIFFERENTIATION SYNDROME WHEN PRESCRIBING AGIOS' TIBSOVO.  Full Article

Celgene Corp - Ozanimod Rms NDA & Maa Submissions On Track For Q1 2019
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Celgene Corp ::CELGENE CORP - OZANIMOD RMS NDA & MAA SUBMISSIONS ON TRACK FOR Q1 2019 - PRESENTATION SLIDE.  Full Article

Celgene reports Q3 EPS at $1.50
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Celgene Corp ::CELGENE REPORTS THIRD QUARTER 2018 OPERATING AND FINANCIAL RESULTS.Q3 REVENUE $3.892 BILLION VERSUS I/B/E/S VIEW $3.85 BILLION.Q3 EARNINGS PER SHARE $1.50.Q3 EARNINGS PER SHARE VIEW $2.22 -- THOMSON REUTERS I/B/E/S.REVLIMID SALES FOR Q3 INCREASED 18 PERCENT TO $2,449 MILLION.QTRLY ADJUSTED EARNINGS PER SHARE $2.29.RAISING FULL-YEAR TOTAL REVENUE GUIDANCE TO ABOUT $15.2 BILLION AND OTEZLA NET PRODUCT SALES TO ABOUT $1.6 BILLION.OTEZLA SALES FOR Q3 WERE $432 MILLION, A 40 PERCENT INCREASE YEAR-OVER-YEAR.SEES 2018 GAAP DILUTED EPS $5.25-$5.75.SEES FY GAAP DILUTED EPS $5.25-$5.75.SEES 2018 ADJUSTED DILUTED EPS $8.75-$8.80.FY2018 EARNINGS PER SHARE VIEW $8.76, REVENUE VIEW $15.17 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Oncomed Provides Update On Navicixizumab Partnership
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - OncoMed Pharmaceuticals Inc ::ONCOMED PROVIDES UPDATE ON NAVICIXIZUMAB PARTNERSHIP.ONCOMED PHARMACEUTICALS - CELGENE NOTIFIED CO IT DECIDED NOT TO EXERCISE ITS OPTION TO LICENSE CO'S BISPECIFIC ANTIBODY NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS INC - ONCOMED AND CELGENE ARE WORKING TO FORMALIZE TERMINATION OF COLLABORATION AGREEMENT WITH RESPECT TO NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS - CELGENE CONTINUES TO RETAIN ITS OPTIONS TO LICENSE ONCOMED'S ETIGILIMAB UNDER COLLABORATION.ONCOMED PHARMACEUTICALS INC - EXPECTS TO RETAIN WORLDWIDE RIGHTS TO NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS INC - ONCOMED EXPECTS TO RETAIN WORLDWIDE RIGHTS TO NAVICIXIZUMAB.  Full Article

Celgene Says Otezla Showed Meaningful Improvements Psoriasis Patients
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Celgene Corp ::OTEZLA® (APREMILAST) SHOWED MEANINGFUL IMPROVEMENTS IN CLINICAL AND QUALITY-OF-LIFE MEASURES OF PSORIASIS BEYOND THOSE CAPTURED BY ASSESSING SKIN ALONE.CELGENE - PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS SHOWED MEANINGFUL IMPROVEMENTS IN SKIN, ITCH, OTHERS AMONG PASI 75 NON-RESPONDERS TREATED WITH OTEZLA.CELGENE CORP - SEPARATE POST HOC SUB-ANALYSIS OF DATA FROM PHASE 3 ESTEEM 1 & 2 &PHASE 4 UNVEIL TRIALS SHOWED IMPROVEMENT WITH OTEZLA VERSUS PLACEBO.  Full Article

Agios Pharmaceuticals - Co, Celgene Agreed To Terminate Collaboration, License Deal
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS PHARMACEUTICALS INC - ON SEPT 4, CO, CELGENE AGREED TO TERMINATE COLLABORATION AND LICENSE DEAL DATED APRIL 27, 2015 BETWEEN CO AND CELGENE.AGIOS PHARMA- FOR SPECIFIED PERIOD CELGENE SHALL BE PROHIBITED FROM DEVELOPING, COMMERCIALIZING PRODUCT THAT INHIBITS ISOCITRATE DEHYDROGENASE 1.AGIOS - ON SEPT 4, CO, CELGENE ALSO AGREED TO TERMINATE LICENSE AGREEMENT DATED APRIL 27, 2015 BETWEEN CO'S UNIT AND CELGENE INTERNATIONAL II SARL.AGIOS PHARMACEUTICALS INC - PROHIBITED PRODUCTS APPLY FOR INHIBITS ISOCITRATE DEHYDROGENASE 1 AT SPECIFIED LEVELS OF BINDING FOR ANY INDICATION.AGIOS PHARMACEUTICALS INC - COMPANY SHALL BE PROHIBITED FROM DEVELOPING, MANUFACTURING OR COMMERCIALIZING AG-881 IN HEMATOLOGIC INDICATIONS.AGIOS PHARMACEUTICALS - FROM & AFTER AG-881 AGREEMENT TERMINATION DATE, CO TO OBTAIN SOLE GLOBAL RIGHTS TO AG-881 - SEC FILING.AGIOS PHARMACEUTICALS - NO PARTY TO HAVE FINANCIAL OBLIGATION TO OTHER PARTIES, INCLUDING MILESTONES, ROYALTIES, OTHER PAYMENTS AFTER TERMINATION DATE.  Full Article

• BLUEBIRD BIO SAYS CELGENE AMENDED PHASE 2 STUDY PROTOCOL
Thursday, 12 Jul 2018 

July 12 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO - CO, CELGENE CONTINUE TO ANTICIPATE A POTENTIAL APPROVAL OF BB2121 PRODUCT CANDIDATE IN RELAPSED & REFRACTORY MULTIPLE MYELOMA IN 2020.BLUEBIRD BIO SAYS CELGENE HAS AMENDED STUDY PROTOCOL FOR KARMMA STUDY, AN ONGOING PHASE 2 STUDY OF BB2121 PRODUCT CANDIDATE - SEC FILING.BLUEBIRD BIO - DOSE RANGE FOR KARMMA STUDY WILL BE 150 TO 450 X 10(6)CAR+ T CELLS AND ENROLLMENT WILL INCREASE TO UP TO 140 PATIENTS.BLUEBIRD BIO INC - IN ADDITION, CELGENE HAS AMENDED STUDY PROTOCOL FOR CRB-401, AN ONGOING PHASE I STUDY OF BB2121 PRODUCT CANDIDATE.BLUEBIRD BIO INC - ENROLLMENT FOR CRB-401 STUDY WILL BE INCREASED BY UP TO 20 PATIENTS, WITH A DOSE RANGE OF 150 TO 450 X 10(6)CAR+ T CELLS.  Full Article

Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Celgene Corp ::ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY.CELGENE CORP - PHASE III IMPASSION130 STUDY, WHICH WAS SPONSORED BY ROCHE, MET ITS CO-PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.CELGENE - OVERALL SURVIVAL IS ENCOURAGING IN PD-L1 POSITIVE POPULATION AT INTERIM ANALYSIS, FOLLOW UP WILL CONTINUE UNTIL NEXT PLANNED ANALYSIS.CELGENE CORP - SAFETY IN TECENTRIQ PLUS ABRAXANE ARM APPEARED CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES.CELGENE CORP - NO NEW SAFETY SIGNALS WERE IDENTIFIED WITH IN TECENTRIQ PLUS ABRAXANE COMBINATION.CELGENE CORP - DATA DEMONSTRATE POTENTIAL ROLE OF ABRAXANE AS PREFERRED CHEMOTHERAPY PARTNER FOR IMMUNOTHERAPY COMBINATIONS.  Full Article

Celgene And Acceleron says Luspatercept Achieved main goals in study
Monday, 9 Jul 2018 

July 10 (Reuters) - Celgene Corp ::CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III ‘BELIEVE’ STUDY IN ADULTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA.CELGENE CORP - RESULTS SHOWED A SIGNIFICANT REDUCTION IN TRANSFUSION BURDEN COMPARED TO PLACEBO.CELGENE CORP - REGULATORY SUBMISSIONS PLANNED IN UNITED STATES AND EUROPE IN FIRST HALF OF 2019.CELGENE CORP - SAFETY PROFILE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED DATA.CELGENE CORP - ADVERSE EVENTS OBSERVED IN STUDY WERE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED DATA.CELGENE CORP - DATA FROM BELIEVE AND MEDALIST WILL BE SUBMITTED TO A FUTURE MEDICAL MEETING IN 2018.  Full Article

J&J's multiple myeloma drug reduces risk of death in late-stage study

Dec 4 Johnson & Johnson's blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday.